BVF Biovail beats by $0.03, guides Y06 above consensus (25.76 )
Reports Q4 (Dec) earnings of $0.77 per share, excluding non-recurring items, $0.03 better than the Reuters Estimates consensus of $0.74; revenues rose 4.4% year/year to $287.6 mln vs the $264.9 mln consensus. Co issues upside guidance for FY06, sees EPS of $2.30-2.40 vs. $2.13 consensus; sees FY06 revs of $990 mln - $1.07 bln vs. $943.96 mln consensus. Co sees Y06 revenues from Wellbutrin XL of $400-410 mln,sees Y06 revenues from Ultram ER of $75-85 mln
|
 |
 |
|||
 |
 |
||||
رد مع اقتباس
المفضلات